One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Wednesday. The fund bought over 530,000 shares of Fate Therapeutics Inc. (NASDAQ: FATE), as the price of this ETF was down over 2% on the day. Note that this fund is up significantly in the past year.

Specifically, ARK Innovation ETF (NYSEARCA: ARKK) bought 535,305 shares of Fate Therapeutics. At Wednesday’s closing price, this would have valued this purchase at roughly $46.2 million. Even though this is a small fraction of the total holdings, every little bit counts. The fund is up 60% in the past year.

Here’s a look at the other purchases across the ARK ETFs:

Fund	Ticker	Company	Shares
ARKF	PATH	UiPath	279,284
ARKG	SGFY	Signify Health	53,916
ARKG	RXRX	Recursion Pharmaceuticals	204,752
ARKG	RPTX	Repare Therapeutics	18,190
ARKG	QSI	Quantum-Si	359,389
ARKG	MASS	908 Devices	47,945
ARKK	FATE	Fate Therapeutics	535,305
ARKK	COIN	Coinbase Global	20,165
ARKK	TSLA	Tesla	110,731
ARKQ	PATH	UiPath	135,228
ARKW	VUZI	Vuzix	521,151
ARKW	FTCH	Farfetch	599,955
ARKX	AVAV	Aerovironment	23,098
ARKX	PATH	UiPath	25,645

Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.